CEL-SCI

CEL-SCI EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of CEL-SCI (CVM) as of Nov 5, 2026 is -1.25. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.18 — a change of 5.71% (lower).

EV/EBIT

-1.25

YoY

5.71%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of CEL-SCI is 2025 -1.25 . EV/EBIT (Enterprise Value to EBIT) of CEL-SCI was 2024 -1.18 . It decreases by 5.71% lower compared to the previous year.

The CEL-SCI EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-1.52 USD
Jan 1, 2020
-1.06 USD
Jan 1, 2021
-0.88 USD
Jan 1, 2022
-0.87 USD
Jan 1, 2023
-0.98 USD
Jan 1, 2024
-1.18 USD
Jan 1, 2025
-1.25 USD
Jan 1, 2026 (e)
-0.96 USD
The CEL-SCI EV/EBIT history
YEAREV/EBITYoY
est-0.96-23.21%
-1.25+5.71%
-1.18+21.07%
-0.98+12.40%
-0.87-1.14%
-0.88-16.97%
-1.06-30.44%
-1.52-17.53%
-1.85+27.22%
-1.45+19.75%
-1.21+34.22%
-0.90-19.60%
-1.12+287.12%
-0.29-68.13%
-0.91+21.33%
-0.75-59.46%
-1.85-52.93%
-3.93+417.11%
-0.76-41.09%
-1.29-27.53%
-1.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CEL-SCI Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides CEL-SCI's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates CEL-SCI's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots CEL-SCI's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if CEL-SCI grows earnings faster than its peers.

CEL-SCI Stock analysis

What does CEL-SCI do? CEL-SCI Corp develops immunotherapies targeting cancer and infectious diseases, focusing on Multikine for head and neck cancers and anal warts in HIV/HPV co-infected patients, and L.E.A.P.S. technology for influenza and rheumatoid arthritis treatments. The company generates revenue through research and development services, with products like LEAPS-H1N1-DC and CEL-2000/CEL-4000 in clinical development. Its primary customers are pharmaceutical partners and research institutions seeking novel therapeutic solutions. The firm operates within the biotechnology sector, emphasizing immune system activation for disease treatment. Multikine and L.E.A.P.S. therapies represent CEL-SCI's core product pipeline, with Multikine targeting head and neck cancers and cervical dysplasia, while L.E.A.P.S. focuses on pandemic influenza and rheumatoid arthritis. The company monetizes its R&D efforts by advancing these therapies through clinical trials, aiming for partnerships with larger pharmaceutical firms for commercialization. Its segment is defined by the development of investigational drugs and vaccines, with no current commercial products generating direct revenue. CEL-SCI's revenue model relies on securing funding for clinical trials and potential future licensing agreements. The company's focus on immune-based therapies for unmet medical needs attracts interest from biotech investors and collaborative partners. Its product candidates, including LEAPS-H1N1-DC and CEL-2000, are positioned for development into marketable treatments, though no sales have occurred yet. CEL-SCI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CEL-SCI stock

EV/EBIT (Enterprise Value to EBIT) of CEL-SCI is -1.25 in 2025.

EV/EBIT (Enterprise Value to EBIT) of CEL-SCI changed from -1.18 to -1.25, representing a 5.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) CEL-SCI since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s CEL-SCI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CEL-SCI

All Key Metrics — CEL-SCI